Challenges in Polio Eradication: Cost and Vaccine-Derived Polioviruses

Seroconversion rates were similar between intradermally administered fractional doses of inactivated poliovirus vaccine and intramuscularly administered full doses. Circulating vaccine-derived polioviruses remain a challenge.

Polio eradication efforts face many challenges, including cost and the circulation of vaccine-derived polioviruses. Two new studies address these issues.

Jenkins and colleagues analyzed the largest recorded outbreak of paralytic disease associated with circulating vaccine-derived poliovirus (cVDPV), in Nigeria. During an intensified polio surveillance program, they collected stool samples, clinical data, and vaccine histories for all cases of acute flaccid paralysis with onset from January 2005 through June 2009 in children aged <15 years. Polioviruses were analyzed to determine whether they were wild type or vaccine related. Among the 23,004 children with paralysis onset during the study period, 278 tested positive for type 2 cVDPV, and 338…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Challenges in Polio Eradication: Cost and Vaccine-Derived Polioviruses

Topics

Reviewing Author